Rubin et al. 1 report that carotenoid supplementation appears to be safe and effective in producing plasma concentrations similar to those observed in human milk-fed term infants and that adding carotenoids to preterm infant formula may have additional benefits related to retinal neurovascular development and suppression of inflammation.
Lutein, zeaxanthin and meso-zeaxanthin are the main carotenoids in the macula, where they have a protective role against oxidative and light damage. 2 We recently found that oral supplementation of preterm infant with gestational age p32 weeks with 0.5 mg Kg -1 per day of lutein do not influence the occurrence and severity of retinopathy of prematurity (ROP). 3 In the Rubin study, the carotenoids-supplemented formula contains 211 mg per l of lutein, so, assuming that a full enteral feed-preterm infant takes about 150-160 ml Kg -1 per day of formula, we can deduce that the infants supplemented in the study finally received about 0.03 mg Kg -1 per day of lutein. We wonder how the authors explain that this low dose of lutein may affect the severity of ROP and the retinal neurovascular development, as they report that fewer infants developed severe ROP in the supplemented formula (8%) than in the control formula (28%) group, and that the supplemented group had greater rod photoreceptor sensitivity.
The authors do not report data about the incidence in the two study groups of the known risk factors that may affect the occurrence and the severity of ROP other than sepsis and NEC, such as oxygen therapy, duration of mechanical ventilation, fungal infections and blood transfusions.
Moreover, the knowledge of the clinical characteristics of the two study groups, mostly the occurrence of infection at the moment of C-reactive protein determination, may help to exclude that other factors in addition to carotenoids may affect C-reactive protein levels, which is a marker of inflammation. This would be very important to know, as lutein has mainly antioxidant properties, and oxidative processes are only one of the mechanisms of inflammation.
In our experience, preterm infants were supplemented from the 7 th day of life until 40 weeks of post-menstrual age or until discharge, and we found only a significant higher lutein concentration at week 5 and a significant higher zeaxanthin concentration at week 4 in the infants supplemented with respect to the not supplemented infants. Rubin et al. found instead a significant higher lutein concentration during the entire study period in the supplemented infants. In this regard, we ask how were the plasma lipids between the two groups. It is known that lutein is initially absorbed from the gut in the form of chylomicrons. After absorption, lutein is delivered to the liver via the portal circulation and bound to ApoE-containing high-density lipoproteins for subsequent release into the systemic circulation. These Apo E/HDL complexes are finally transported to the retina. 2 It is important to know whether there was any difference in the plasma lipids between the two study groups, that may have influenced the different carotenoid concentrations reported by the authors.
Finally, we would like to know more details about the characteristics of the population and about the lipid profile of infants studied, to conclude that supplementation of formula milk may be responsible for this significant beneficial effect on visual outcome and inflammation status in preterm infants.
